Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients - 08/02/22

Doi : 10.1016/j.neurol.2021.12.008

H. Chaumont ^a,^b,^c,⁎ , E. Meppiel ^d, E. Roze ^c,^e, B. Tressières ^f, T. de Broucker ^d, A. Lannuzel ^a,^b,^c,^f
on behalf of the contributors to the French NeuroCOVID registry^¹
Contributors to the French NeuroCOVID registry are listed to Appendix A.
^a Service de neurologie, Centre hospitalier universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, Guadeloupe
^b Faculté de Médecine de l’université des Antilles, Pointe-à-Pitre, Guadeloupe
^c Sorbonne Université, Institut national de la Santé et de la Recherche médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau, Paris, France
^d Service de Neurologie, Centre hospitalier de Saint-Denis, Hôpital Delafontaine, Saint-Denis, France
^e Département de Neurologie, AP–HP, Hôpital de la Pitié-Salpêtrière, Paris, France
^f Centre d’investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, Guadeloupe

^⁎Corresponding author. Department of Neurology, University Hospital of Guadeloupe, 97139, Pointe-à-Pitre/Abymes, Guadeloupe.Centre d’investigation Clinique Antilles Guyane, Inserm CIC 1424Pointe-à-PitreGuadeloupe

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background and purpose

Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID).

Methods

We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry.

Results

We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR: 1.06, 95% CI: 1.01–1.13, p=0.026). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients.

Conclusions

NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, Neurological manifestation, NeuroCOVID, Post-COVID Syndrome, Long-term outcomes

Plan

Introduction

Methods

Patients and study design

Data collection and neurological investigations

Disclosure of interest

Export

Vol 178 - N° 1-2

P. 137-143 - janvier 2022 Retour au numéro

Article précédent

The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19
M. Fathi, F. Taghizadeh, H. Mojtahedi, S. Zargar Balaye Jame, N. Markazi Moghaddam

| Article suivant

Clinicoradiological and prognostic features of COVID-19-associated acute disseminated encephalomyelitis
J. Oumerzouk, M. Nabil, R. Klevor, S. Belasri, M. Chraa, N. Louhab, N. Kissani

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients - 08/02/22

Abstract

Background and purpose

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL